BXCL504

BXCL504 is an investigational drug candidate being developed by BioXcel Therapeutics for the treatment of aggression in dementia. It is part of BioXcel's neuropsychiatric pipeline, which leverages AI-driven drug re-innovation to address unmet needs in neuropsychiatric and neurodegenerative disorders. While detailed information on its mechanism of action or molecular structure has not been publicly disclosed, BXCL504 is distinct from other candidates in the company's portfolio (such as BXCL501 and BXCL502) and specifically targets aggression symptoms associated with dementia[2][3][5]. As of the latest available information, clinical development status beyond preclinical or early-stage planning has not been reported.